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Abstract 31 
Context  32 
Approximately 20-40% of clinically-defined familial hypercholesterolemia cases do not show a 33 
causative mutation in candidate genes (mutation-negative FH), and some of them may have a 34 
polygenic origin.  35 
Objective 36 
The aim of this work was to study the prevalence of ABCG5/G8 genetic variants in mutation-37 
negative FH, as defects in these genes relate to intesti al hyperabsorption of cholesterol and 38 
thus ABCG5/G8 variants could explain in part the mechanism of hypercholesterolemia. 39 
Design, Setting and patients:  40 
We sequenced the ABCG5/G8 genes in 214 mutation-negative FH and 97 controls. Surrogate 41 
markers of cholesterol absorption (5α-cholestanol, β-sitosterol, campesterol, stigmasterol and 42 
sitostanol) were quantified by high performance liquid chromatography tandem mass 43 
spectrometry in both studied groups.  44 
Results 45 
We found 8 mutation-negative FH patients (3.73%) with a pathogenic mutation in ABCG5/G8 46 
genes. We observed significantly higher concentration of surrogate markers of cholesterol 47 
absorption in mutation-negative FH than in controls. In addition, we found significantly higher 48 
concentrations of cholesterol absorption markers in mutation-negative FH with ABCG5/G8 49 
defects than in mutation-negative, ABCG5/G8 negative FH. A gene score reflecting the number 50 
of common single nucleotide variants associated with hypercholesterolemia was significantly 51 
higher in cases than in controls (p=.032). Subjects with a gene score above the mean had 52 
significantly higher 5α-cholestanol and stigmasterol than those with a lower gene score.  53 
Conclusions  54 
Mutation-negative FH subjects accumulate an excess of rare and common gene variations in 55 














cholesterol, as determined by surrogate makers, sugge ting that these loci contribute to 57 
hypercholesterolemia by enhancing intestinal cholesterol absorption. 58 
Abbreviations  59 
GH: genetic hypercholesterolemias 60 
FH: Familial hypercholesterolemia  61 
TC: Total cholesterol  62 
TG: triglyceride 63 
LDLc: Low density lipoprotein cholesterol 64 
SNVs: single nucleotide variations  65 
CHD: cardiovascular disease  66 
Mutation-negative FH: Familial hypercholesterolemia without mutation in candidate genes  67 
HDLc: High density lipoprotein cholesterol  68 
HPLC-MS/MS: high performance liquid chromatography tandem mass spectrometry  69 
BMI: Body mass index  70 
Apo: Apolipoprotein  71 















Genetic hypercholesterolemias (GH) are a heterogeneous group of lipid disorders caused 74 
by monogenic and polygenic defects and characterized by very high plasma 75 
concentrations of total cholesterol (TC) due to increased low-density lipoprotein 76 
cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). Familial 77 
hypercholesterolemia (FH) is the most common monogeic GH [1], with autosomal 78 
codominant transmission and with a current estimated pr valence of about 1:200-250 in 79 
the general population [2, 3]. FH is caused by mutations in LDLR, the gene coding for the 80 
LDL receptor; APOB, coding for apolipoprotein (apo) B; PCSK9 [4, 5], which codes for 81 
the enzyme proprotein convertase subtilisin/kexin type 9, or APOE genes [6]. In addition, 82 
a rare recessive form of FH is also caused by mutations in the LDLRAP1 gene [7]. 83 
However, a causative mutation in candidate genes is not found in approximately 20-40% 84 
of clinically defined FH cases [8], suggesting that there are either other as yet unidentified 85 
genetic causative loci or these cases represent severe polygenic hyperchol ster lemia. 86 
Actually, affected subjects with clinical FH but without mutations in candidate genes, 87 
accumulate some common single nucleotide variations (SNVs) with a small LDL-C 88 
raising effect [9] that do not fully explain the hig  LDL-C phenotype of these subjects. 89 
  Different GWAS have shown that at least one hundred loci are associated with 90 
LDL-C concentration in the population [10, 11]. One of these loci is ABCG5/G8; this 91 
gene complex encodes the proteins ABCG5 and ABCG8, which form a heterodimer 92 
conveyor located in the membrane of enterocytes and hepatocytes. It has been shown that 93 
ABCG5/G8 limits the intestinal absorption of cholesterol and phytosterols and promotes 94 
their hepatobiliary secretion. Severe functional mutations in ABCG5/G8 cause 95 
sitosterolemia, a rare autosomal disorder characterized by an increase of phytosterols in 96 
blood, up to 30 times greater than normal [12]. In addition, studies have shown that 97 
ABCG5/G8 variation is associated with cholesterol and non-cholesterol sterol plasma 98 
levels [13-17]. However, the contribution of ABCG5/G8 loci variation to mutation-99 














Considering that mutation-negative FH subjects usually h ve higher non-101 
cholesterol sterol concentrations than other types of GH [18], probably due to intestinal 102 
sterol hyperabsorption, we hypothesized that genetic variations in ABCG5/G8 are 103 
involved in some forms of mutation-negative FH. Henc , the aim of this study was to 104 
analyze common and rare mutations in ABCG5/G8 in a large cohort of mutation-negative 105 
FH and assess their association with non-cholesterol sterols and LDL-C, to establish the 106 
genetic contribution of these loci in this type of GH.  107 
Material and Methods 108 
Subjects  109 
Unrelated subjects (n = 214) 18–79 years of age with a clinical diagnosis of non-FH GH: 110 
LDL-C above the 95th percentile of the Spanish population [19], triglycerides (TG) 111 
below 200 mg/dL, and familial presentation (at least one first-degree relative with the 112 
same phenotype) from the Lipid Clinics at Hospital Universitario Miguel Servet, 113 
Zaragoza and Hospital Clinic, Barcelona were selectd for this study. In all subjects, the 114 
absence of a pathogenic mutation in LDLR, APOB and PCSK9 genes was confirmed by 115 
the Lipochip ® platform [20]. Exclusion criteria were the presence of an ε2/ε2 genotype 116 
or the p.(Leu167del) mutation in the APOE gene. Exclusion criteria were secondary 117 
causes of hypercholesterolemia including obesity (body mass index >30 kg/m2), poorly 118 
controlled type-2 diabetes (HbA1c >8%), renal disease with glomerular filtration rate <30 119 
ml/min and/or macroalbuminuria, liver diseases (ALT> 3 times upper normal limit), 120 
hypothyroidism (TSH >6 mIU/L), pregnancy, autoimmune diseases and treatment with 121 
protease inhibitors. Assessment of cardiovascular risk factors, personal and family history 122 
of cardiovascular disease, intake of drugs affecting intestinal or lipid metabolism, and 123 
anthropometric measurements were performed in all participants. The normolipemic 124 
group (n= 97) consisted of healthy, unrelated men and women volunteers aged 18–79 125 
years, who underwent a medical examination at the Hospital Miguel Servet of Zaragoza. 126 
Exclusion criteria for control subjects were personal or parental history of premature 127 














influence glucose or lipid metabolism. All subjects signed an informed consent to a 129 
protocol previously approved by our local ethics committee (Comité Ético de 130 
Investigación Clínica of Aragón, Zaragoza, and of Hspital Clínic, Barcelona, Spain). 131 
Clinical and laboratory determinations 132 
Cases and controls were assessed for personal and familial history of cardiovascular 133 
disease, medication use and cardiovascular risk factors. EDTA plasma and serum samples 134 
were collected after 10-12 hours of fasting in all p rticipants after at least 6 weeks 135 
without lipid-lowering drugs in subjects without prior cardiovascular disease. TG levels 136 
were determined by standard enzymatic methods. High-density lipoprotein cholesterol 137 
(HDL-C) was measured directly by an enzymatic reaction using cholesterol oxidase 138 
(UniCel DxC 800; Beckman Coulter, Inc., Brea, CA, USA). Lipoprotein(a), apo A1, apo 139 
B and C-reactive protein were determined by IMMAGE kinetic nephelometry (Beckman-140 
Coulter, Inc.). In patients with prior cardiovascular disease, baseline lipid values were 141 
obtained from medical records. 142 
Genetic analysis  143 
Whole blood genomic DNA was isolated by using standard methods. Promoters, coding regions 144 
and intron-exon boundaries of ABCG5 (NM_022436) and ABCG8 (NM_022437) were 145 
amplified by PCR and purified by ExoSap-IT (USB). Amplified fragments were sequenced by 146 
the Sanger method using the BigDye 3.1 sequencing kit (Applied Biosystems) in an automated 147 
ABI 3500xL sequencer (Applied Biosystems). DNA sequnces were analyzed using 148 
VariantReporterTM software (Applied Biosystems). APOE genotypes were determined by DNA 149 
sequencing of exon 4 as previously described [21].  150 
To evaluate the pathogenicity of new identified genetic variants, we used PolyPhen-2 [22] 151 
and Mutation Taster [23]. The effect of variants in potential splicing sites was predicted 152 
with NetGene2 [24] and NNSplice [25]. We refer to non-synonymous variants as 153 
sequence variations causing amino acid substitutions (missense variants) or introducing a 154 
premature stop codon (nonsense variants). Intronic var ants were considered when they 155 














 In order to compare the frequency of identified variants in the general population 157 
we have compiled the allele frequencies of the ident fi d variants from the 1000 Genomes 158 
Project [26] and ExAc Browser Data [27].  159 
 Mutations were defined as genetic variants with a frequency lower than 1% in the 160 
general population. A mutation was defined as pathogenic when it was not present in 161 
controls and bioinformatic analysis prediction defin d it as “damaging” (Polyphen-2) or 162 
“disease causal” (MutationTaster). Single Nucleotide Polymorphism (SNP), was defined 163 
as genetic variants with a frequency higher than 1% in the general population.  164 
Gene score 165 
A gene score using the sum of the risk alleles of 27 genetic variants with allelic 166 
frequencies statistically different between cases and controls was calculated for each 167 
subject.  168 
Determination of serum sterols 169 
Serum concentrations of cholesterol, 5α-cholestanol, β-sitosterol, campesterol, 170 
stigmasterol, sitostanol, desmosterol and lanosterol were quantify by high performance 171 
liquid chromatography tandem mass spectrometry (HPLC-MS/MS) in 206 non-FH GH 172 
subjects without lipid-lowering drugs and 97 controls according to the method previously 173 
described [28]. In 8 subjects non-cholesterol sterols were not quantified because 7 had 174 
prior CHD and one had not provided a serum sample. Data were expressed as mg/dL, as 175 
well as normalized to total cholesterol. Briefly, 100 µL of serum were transferred to 176 
screw-capped vials, and 6 µl of deuterium-labeled internal standard, [2H6] cholesterol-177 
26,26,26,27,27,27 (7.9 mM) for non-cholesterol sterols, and [2H7] cholesterol-178 
25,26,26,26,27,27,27 for cholesterol, were added. Alkaline hydrolysis was performed for 179 
20 min at 60ºC in an ultrasound bath, followed by a double extraction with 3 µl of 180 
hexane. The extract was loaded onto the solid-phase extraction cartridge (1 mg, 181 
Discovery DSC-18, Supelco, Spain), which was preconditioned with 400 µl of methanol 182 














of 2-propanol by gravity, and 40 µL of the final mixture was injected into the HPLC-184 
MS/MS system. 185 
Statistical Analyses 186 
Analyses were performed using SPSS version 20.0 (Chicago, Ilinois, USA). The nominal 187 
level for significance was p< 0.05. Normal distribution of variables was analyzed by the 188 
Kolmogorov–Smirnov test. Quantitative variables with normal distribution were 189 
expressed as mean ± standard deviation and were analyzed with Student t-test. Variables 190 
with a skewed distribution were expressed as medians and interquartile ranges and were 191 
analyzed with the Mann-Whitney U test. Qualitative variables were expressed as a 192 

















 Results 197 
The main clinical and biochemical characteristics of the two groups: 214 mutation-negative FH 198 
patients and 97 normolipemic controls are presented i  Table 1. By study design, compared to 199 
normolipidemic controls, mutation-negative FH participants had significantly higher values of 200 
total cholesterol, triglycerides, HDL-C, LDL-C, lipo rotein(a), and apo B, as well as a higher 201 
prevalence of hypertension and cardiovascular disease. No differences in age, body mass index 202 
(BMI) or APOE genotype variability were found between patients ad controls.  203 
Non-cholesterol sterol-to-TC ratios are presented in Table 2. 5α-cholestanol, 204 
stigmasterol and sitostanol ratios were significantly higher in cases than in controls (p=.023, 205 
p<.001 and p=.003, respectively). The sum of all cholesterol absorpti n surrogate markers and 206 
phytosterols was also significantly higher in mutation-negative FH than in controls (p= .028).  207 
The frequency of SNVs in ABCG5/G8 genes found in mutation-negative FH was 208 
compared to the frequency in controls, in the 1000 Genomes Project and ExAc Browser Data. 209 
Appendix table 1 shows the 29 SNVs identified which allelic frequencies were significantly 210 
different from those identified in controls or described in the 1000 Genomes Project or in the 211 
ExAc Browser Data. They include 27 SNPs and two mutations: p.(Gly269Arg) in ABCG5 and 212 
p.(Gly512Arg) in ABCG8. 213 
Table 3 shows the clinical characterization of patients carrying pathogenic mutations 214 
identified by sequencing in ABCG5 and ABCG8. A total of eight patients out of 214 (3.73%) 215 
were carriers of 6 pathogenic mutations: p.(Asn578Ser), p.(Gly288Arg), p.(Arg198Gln), 216 
p.(Gly269Arg), and p.(Asn285Ser) in ABCG5 and p.(Gly512Arg) in ABCG8. One of them is 217 
described for the first time in this work: p.(Asn578Ser) in ABCG5. None of these pathogenic 218 
mutations were present in controls. Appendix table 2 shows bioinformatic analysis of six 219 
pathogenic mutations.  220 
Subjects with mutation-negative FH with pathogenic mutations in ABCG5/G8 genes 221 
had significantly higher non-cholesterol sterol-to-TC ratios (5α-cholestanol, β-sitosterol, 222 
campesterol, and stigmasterol) and cholesterol absorption than subjects without mutation in 223 














concentrations did not show significant differences b tween the groups (Table 4). There were no 225 
differences in desmosterol and lanosterol, cholesterol synthesis markers, between both groups 226 
(Supplemental Table 3). In one out of eight patients wi h mutation-negative FH with pathogenic 227 
mutation in ABCG5/G8 genes, cholesterol absorption markers were not determined because 228 
serum without lipid lowering drugs was not available.  229 
Among the 27 common genetic variants with significantly different frequencies between 230 
cases, 1000 Genomes Project and ExAc Browser Data, only c.*380T>G, located in the 3´ UTR 231 
of ABCG5 gene was associated with statistically significant differences in non-cholesterol sterol 232 
to TC ratios (5α-cholestanol, β-sitosterol, stigmasterol and campesterol) and cholesterol 233 
absorption. T allele carriers had higher intestinal cholesterol absorption than subjects carrying 234 
the G allele (p=.011, p=.00, p=.002, p=.022 and p=.002, respectively), but TC concentrations 235 
were not significantly different between genotypes (Table 5). 236 
A gene score reflecting the total number of risk alleles at the 27 SNVs associated with 237 
hypercholesterolemia was significantly higher in cases than controls (p=.032). Subjects with 238 
scores above the mean (>33 points) had significantly higher non-cholesterol sterol to TC ratios 239 
(5α-cholestanol and stigmasterol) than subjects with the lowest score (p=.034 and p=.029, 240 
respectively). Cholesterol absorption was non-significantly higher in subjects with the highest 241 
















This study shows that ABCG5/G8 gene variation would play a role in the pathogenesis of 245 
genetic hypercholesterolemia unrelated to LDLR, APOB, PCSK9 and APOE genes. As 246 
previously reported [29], subjects with GH unrelated to common genetic defects disclose higher 247 
surrogate markers of intestinal cholesterol absorption than controls. There are, however, three 248 
novel findings that can be highlighted from this work. 249 
First, ABCG5/G8 genetic variation contributes to GH through rare pathogenic mutations 250 
with large effects and with common variants with small effects. Patients with rare ABCG5/G8 251 
pathogenic mutations disclose approximately twice the serum concentrations of surrogate 252 
markers of intestinal cholesterol absorption than those not carrying mutations. However, the 253 
percentage of common mutation-negative FH subjects carrying these rare pathogenic 254 
ABCG5/G8 mutations is low, approximately 4%. We did not find any pathogenic mutation in 255 
the control group; hence we could consider that these major defects are involved in the high 256 
LDL-C phenotype in these patients. However, we must take into account that there could be 257 
other SNVs in other genes, which could explain partof the phenotype of these subjects, and the 258 
number of normolipemic controls in not high enough to exclude completely their presence in 259 
the normolipemic population. We found 8 patients carrying six pathogenic mutations. Five 260 
mutations were in ABCG5 and one mutation was in ABCG8. The mutations p.(Arg198Gln), 261 
p.(Gly269Arg), p.(Asn296Ser) and p.(Gly288Arg) in ABCG5 are located in the cytosolic N-262 
terminal region, prior to the first transmembrane domain. In this N-terminal region of ABCG5, 263 
one mutation causing sitosterolaemia has been previously described [30]. The mutation 264 
p.(Asn578Ser) in ABCG5 is located in the extracellular domain, and this position seems to 265 
interact with the amino acid Arg419. The mutations p.(Arg419Pro) and p.(Arg419His) at the 266 
same residue have been shown to cause sitosterolaemia. The mutation p.(Gly512Arg) in ABCG8 267 
is located in the transmembrane α-helix domain; a close mutation in this domain, 268 
p.(Leu501Pro), also causes sitosterolaemia [31].   269 
Second, our results show that mutation-negative FH subjects accumulate risk alleles of 270 














cases, the contribution of ABCG5/G8 genetic variation has a limited effect within a polygenic 272 
background, as occurs in other genetic dyslipidemias [32]. Among common SNVs frequently 273 
found in mutation-negative FH, only one SNVs in 3´UTR showed significant variations in non-274 
cholesterol sterols by itself. Variants in 3´UTR have been previously involved in the 275 
pathogenesis of some mutation-negative FH. An important mechanism of post-transcriptional 276 
regulation linked to the 3´UTR implicates the binding of microRNAs (miRNAs), small non-277 
protein coding RNAs that regulate gene expression at the post-transcriptional level. [33]. The 278 
frequency of the c.*380T>G variant in ABCG5, located in 3´UTR, is significantly lower in 279 
mutation-negative FH than in controls, and T allele carriers had higher intestinal cholesterol 280 
absorption than subjects carrying the G allele. The c.*380T>G variant has been previously 281 
associated with sitosterolaemia [34]. The mir-494 is a miRNA, which has been previously 282 
associated with this variant [35]. Bioinformatic analysis of this variant showed that T allele 283 
carriers disclose mir-494, which is not present in G allele carries. For this reason, we propose 284 
that mir-494 could regulate the absorption of non-cholesterol sterols and could explain in part 285 
the pathogenesis of the hypercholesterolemia in these subjects.  286 
Finally, our study supports the multifactorial origin of most mutation-negative FH, in 287 
whom intestinal hyperabsorption of sterols plays a minor role that does not fully explain the 288 
etiology of these hypercholesterolemias, and with different contributions among subjects 289 
depending on the number of risk alleles they carry. Those subjects that accumulate many risk 290 
alleles of ABCG5/G8 show a clearer hyperabsorption mechanism that could explain some of the 291 
LDL-C variation. We have recently analyzed a group f mutation-negative FH families with 292 
hyperabsorption in the proband. The cosegregation analysis showed a substantial contribution of 293 
hyperabsorption on the LDL-C concentration, although with high variation among the families 294 
[29].  295 
An interesting issue is the potential relationship between ABCG5/G8 gene variation and 296 
CHD risk. The C allele of the c.1199C>A, p.(Thr400Lys) variant in ABCG8 has been 297 
previously associated with CHD [36]. In our study, the frequency of this risk allele variant was 298 














suggesting that the association with CHD previously reported could be mediated by its effect on 300 
LDL-C. However, the association of plasma phytosterols with CHD has not been clearly 301 
established [37]. Actually, none of 8 subjects with severe pathogenic mutations in ABCG5/G8 in 302 
our study had CHD. Further studies are required to es ablish the potential association of 303 
ABCG5/G8 variation and atherosclerosis.  304 
Our study has limitations: We have not performed functional studies of the ABCG5/ABCG8 305 
variants detected, but due to their large number thei analysis would require a different 306 
approach. We have analyzed surrogate markers for intesti al cholesterol absorption; although 307 
very well validated; they have some limitations, and may be influenced by diet, sex, age, BMI, 308 
and APOE genotype. However, the differences in non-cholesterol sterols between mutation-309 
negative FH subjects and controls and between patients with and without pathogenic 310 
ABCG5/G8 mutations were not modified by any of these confouding factors. Subjects with 311 
hyperabsorption-associated ABCG5/G8 mutations had no higher LDL cholesterol 312 
concentrations than the other hypercholesterolemic subjects of genetic cause. Our interpretation 313 
is that hypercholesterolemias with hyperabsorption d  ot present a more severe phenotype than 314 
those other genetic forms not associated with this mechanism and by the moment of unknown 315 
origin. 316 
In conclusion, the sequencing analysis of a large goup of subjects with genetic 317 
hypercholesterolemia and no pathogenic mutation in LDLR, APOB, PCSK9 or APOE genes, 318 
shows that they accumulate an excess of rare and common gene variations in ABCG5/G8 genes. 319 
This variation is associated with surrogate markers of increased intestinal cholesterol 320 
absorption, suggesting that these loci contribute to their hypercholesterolemia by raising 321 
intestinal cholesterol absorption.  322 
Financial support  323 
This study was supported by grants from the Spanish M nistry of Economy and 324 
Competitiveness PI15/01983, PI13/02507, PI12/01321, CIBERCV, CIBEROBN and Cuenca 325 














European Regional Development Fund (ERDF) of the European Union "A way to make 327 
Europe".  328 
Disclosure summary 329 
I certify that neither I nor my co-authors have a conflict of interest as described above that is 330 
relevant to the subject matter or materials included in this work. 331 
Author contributions  332 
ILM performed the experiments and contributed to the writing of the manuscript. FC 333 
contributed substantially to the conception and design and to the writing of the 334 
manuscript; all authors participated in acquisition, a alysis and interpretation of the data, 335 
in the drafting of the article or critical revision and in final approval of the version to be 336 
published.  337 
Acknowledgments 338 
Genetic analyses were performed in the Sequencing and Functional Genomics Facility of 339 
Servicios Científico Técnicos of CIBA (IACS-Universidad de Zaragoza), Zaragoza, 340 





1. Goldstein JK, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, 346 
Beaudet AL, Sly WS, Valle D (eds). The Metabolic & Molecular Bases of Inherited 347 
Disease. 8th ed. New York: McGraw-Hill; 2001. p. 2863–2913. 348 
2. De Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. 349 
Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States 350 















3. Akioyamen LE , Genest J, Shan SD, Reel RL, Albaum JM, Chu A et al. Estimating the 353 
prevalence of heterozygous familial hypercholesterola mia: a systematic review and 354 
meta-analysis. BMJ Open. 2017; 1:7-9.  355 
4. Civeira F. International Panel on Management of Famili l Hypercholesterolemia. 356 
Guidelines for the diagnosis and management of heterozygous familial 357 
hypercholesterolemia. Atherosclerosis. 2004; 173:55-68. 358 
5. Futema M, Plagnol V, Li K, Whittall RA, Neil HA, Seed M, Simon Broome 359 
Consortium, Bertolini S, Calandra S, Descamps OS, Graham CA, Hegele RA, Karpe F, 360 
Durst R, Leitersdorf E, Lench N, Nair DR, Soran H, Van Bockxmeer FM1; UK10K 361 
Consortium, Humphries SE. Whole exome sequencing of familial 362 
hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med 363 
Genet. 2014;515:37-44. 364 
6. Cenarro A, Etxebarria A, de Castro-Orós I, Stef M, Bea AM Palacios L, Mateo-Gallego 365 
R, Benito-Vicente A, Ostolaza H, Tejedor T, Martín C, Civeira F. The p.Leu167del 366 
mutation in APOE gene causes Autosomal Dominant Hypercholesterolemia by down-367 
regulation of LDL receptor expression in hepatocytes. J Clin Endocrinol Metab. 2016; 368 
101:2113-21. 369 
7. Ciccarese MA, Pacifico G, Tonolo G, Pintus P, Nikoshkov A, Zuliani G, Fellin R, 370 
Luthman H and Maioli M. A new locus for autosomal recessive hypercholesterolemia 371 
maps to human chromosome 15q25-q26. Am J Hum Genet. 2000; 66:453-460.  372 
8. Palacios L, Grandoso L, Cuevas N, Olano-Martín E, Martinez A, Tejedor D, Stef M. 373 
Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis. 374 
2012;221:137-42. 375 
9. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, 376 
Li K, Drenos F, Karpe F, Neil HA, Descamps OS, Lange berg C, Lench N, 377 
Kivimaki M, Whittaker J, Hingorani AD, Kumari M, Humphries SE. Use of low-378 














and monogenic familial hypercholesterolemia: a case-control study. Lancet. 380 
2013; 381:1293-301.  381 
10. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM Koseki M  et al. 382 
Biological, clinical and population relevance of 95loci for blood lipids. Nature 2010; 383 
466:707–13. 384 
11. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafs on S Kanoni S et al. 385 
Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45:1-24. 386 
12. Yu , L. , J. Li-Hawkins , R. E. Hammer , K. E. Berg , J. D. Horton , J. C. Cohen , and 387 
H. H. Hobbs. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol 388 
secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 2002; 389 
110:671–80 . 390 
13. Lily Jakulj , 1, Maud N. Vissers , Michael W. T. Tanck , Barbara A. Hutten , Frans 391 
Stellaard , John J. P. Kastelein , Geesje M. Dallinga-Thie. ABCG5/G8 polymorphisms 392 
and markers of cholesterol metabolism: systematic review and meta-analysis. J Lipid 393 
Res. 2010;51:3016-26.  394 
14. Berge , K. E., K. von Bergmann, D. Lutjohann, R. Guerra, S. M. Grundy, H. H. Hobbs, 395 
and J. C. Cohen. Heritability of plasma non-cholesterol sterols and relationship to DNA 396 
sequence polymorphism in ABCG5 and ABCG8. J. Lipid Res 2002; 43: 486–94. 397 
15. Hubacek , J. A. , K. E. Berge , J. Stefkova , J. Pitha , Z. Skodova , V. Lanska , and R. 398 
Poledne. Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol 399 
levels. Physiol. Res. 2004;53:395–401. 400 
16. Weggemans RM, Zock PL, Tai ES, Ordovas JM, Molhuizen HO, Katan MB. ATP 401 
binding cassette G5 C1950G polymorphism may affect blood cholesterol concentrations 402 
in humans. Clin. Genet. 2002;62:226–229. 403 
17. Chen ZC, Shin SJ, Kuo KK, Lin KD, Yu ML, Hsiao PJ. Significant association of 404 
ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance. J. 405 














18. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J et al. Comparison of genetic 407 
versus clinical diagnosis in familial hypercholesterol mia. Am J Cardiol. 408 
2008;102(9):1187-93. 409 
19. Wu G, Li GB, Yao M, Zhang DQ, Dai B, Ju CJ, Han M. ABCG5/8 variants are associated 410 
with susceptibility to coronary heart disease. Mol Med Rep. 2014;6:2512-20.  411 
20. Stef MA, Palacios L, Olano-Martín E, Foe-A-Man C, van de Kerkhof L, Klaaijsen LN, 412 
Molano A, Schuurman EJ, Tejedor D, Defesche JC. A DNA microarray for the 413 
detection of point mutations and copy number variation causing familial 414 
hypercholesterolemia in Europe. J Mol Diagn. 2013;15:362-72. 415 
21. Solanas-Barca M, De Castro-orós I, Mateo-Gallego R, Cofán M, Plana N Puzo J 416 
et al. Apolipoprotein E gene mutations in subjects wi h mixed hyperlipidemia and 417 
a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis. 2012; 418 
222::449-55. 419 
22. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A 420 
method and server for predicting damaging missense mutations. Nat Methods. 421 
2010;7:248–49. 422 
23. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates 423 
disease-causing potential of sequence alterations. Nat Methods. 2010;7:575-6. 424 
24. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor 425 
sites from the DNA sequence. J Mol Biol. 1991;220:49–65. 426 
25. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection inGenie. J 427 
Comput Biol. 1997;4:311–23. 428 
26. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, 429 
Durbin RM. An integrated map of genetic variation from 1,092 human genomes. 430 
Nature. 2012;491:56–65. 431 
27. Monkol Lek, Konrad J. Karczewski, Eric V. Minikel, Kaitlin E. Samocha, Eric Banks, 432 
Timothy Fennell et al. Analysis of protein-coding genetic variation in 60,706 humans. 433 














28. Baila-Rueda L, Cenarro A, Cof_an M, et al. Simultaneous determination of oxysterols, 435 
phytosterols and cholesterol precursors by high performance liquid chromatography 436 
tandem mass spectrometry in human serum. Analytical Methods. 2013;5:2249–2257. 437 
29. Baila-Rueda L, Cenarro A, Lamiquiz-Moneo I, Mateo-Gallego R, Bea AM, Perez-438 
Calahorra S, Marco-Benedí V, Civeira F. Bile acid synthesis precursors in subjects with 439 
genetic hypercholesterolemia negative for LDLR/APOB/PCSK9/APOE mutations. 440 
Association with lipids and carotid atherosclerosis. J Steroid Biochem Mol Biol. 441 
2016;16:30263-71.  442 
30. Hubacek JA, Berge KE, Cohen JC, Hobbs HH. Mutations in ATP-cassette binding 443 
proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum Mutat. 444 
2001;4:359-60. 445 
31. Jyh-Yeuan Lee, Lisa N. Kinch, Dominika M. Borek, Jin Wang, Junmei Wang, Ina L. 446 
Urbatsch, Xiao-Song Xie, Nikolai. Grishin, Jonathan C. Cohen, Zbyszek Otwinowski, 447 
Helen H. Hobbs, and Daniel M. Rosenbaum. Crystal structure of the human sterol 448 
transporter ABCG5/ABCG8. Nature. 2016;533:561–64. 449 
32. De Castro-Orós I, Cenarro A, Tejedor MT, Baila-Rueda L, Mateo-Gallego R, 450 
Lamiquiz-Moneo I, Pocoví M, Civeira F. Common genetic variants contribute to 451 
primary hypertriglyceridemia without differences betw en familial combined 452 
hyperlipidemia and isolated hypertriglyceridemia. Circ Cardiovasc Genet. 2014;7:814-453 
21.  454 
33. Perez-Campo F; De Castro-Orós I; Noriega A; Cofán M; Lamiquiz-Moneo I; Cenarro 455 
A; Ros E; Civeira F; Pocoví M; Rodríguez-Rey JC. Functional analysis of new 3´UTR 456 
genetic variants in genes associated with hypercholesterolemias. J Clin Lipidol. 2017 457 
[In press].  458 
34. NCBI ClinVar. https://www.ncbi.nlm.nih.gov/clinvar/variation/336031/ 459 
35. PolymiRTS Database 3.0.  http://compbio.uthsc.edu/miRSNP/miRSNP_detail_all.php 460 
36. Wu G, Li GB, Yao M, Zhang DQ, Dai B, Ju CJ, Han M. ABCG5/8 variants are 461 














37. Jeemon P, Pettigrew K, Sainsbury C, Prabhakaran D, Padmanabhan S. Implications of 463 
discoveries from genome-wide association studies in current cardiovascular practice. 464 















Table 1. Clinical and biochemical characteristics of controls and mutation-negative FH.  
Quantitative variables are expressed as means ± standard deviations, except for variables not 
following normal distribution that are expressed as medians (interquartile ranges). Qualitative 
variables were expressed as %. The p value was calculated by Student's t test or Mann-Whitney 
U and Chi-square, as appropriate. 
HPLC-MS/MS: high performance liquid chromatography tandem mass spectrometry.  
 
 Controls  
(n = 97) 
Mutation-negative 
FH  
(n = 214 ) 
p 
Age, years 44.5 ± 17.3 47.0 ±12.4 0.135 
Men, n (%) 37 (38.1) 112 (47.6) 0.020 
Body mass index, kg/m2 25.3 ± 4.59 24.5 ± 2.69 0.149 
Total cholesterol by HPLC 
MS/MS, mg/dL 
201 ± 45.3 302 ± 59.8 <0.001 
Triglycerides, mg/dL 75.0 (49.0-103) 112 (86.0-157) <0.001 
LDL cholesterol, mg/dL 122 (114-146) 224 (205-244) <0.001 
HDL cholesterol, mg/dL 53.0 (45.0-64.3) 55.0 (47.0-68.0) 0.042 
Lipoprotein(a), mg/dL 15.7 (7.26-30.6) 44.3 (16.1-98.4) <0.001 
Apolipoprotein B, mg/dL 98.8 ± 20.0 154 ± 32.3 <0.001 
Apolipoprotein A1, mg/dL 157 (138-177) 157 (137-180) 0.503 
Glucose, mg/dL 85.5 (79.0-92.0) 87.0 (82.0-96.0) 0.169 
Hypertension, n (%) 6 (6.38) 32 (15.0) 0.035 
Diabetes, n (%) 0 (0) 1 (0.47) 0.509 
Cardiovascular disease, n (%) 0 (0) 7 (3.27) 0.073 
Tobacco, n 
(%) 
Non smoker 53 (54.6) 100 (46.7) 
0.330 Current smoker 22 (22.7) 61 (28.5) 




E2/E3 10 (10.3) 14 (6.54) 
0.107 
E3/E3 69 (71.1) 136 (63.5) 
E4/E3 15 (15.5) 57 (26.6) 
E4/E4 1 (1.03) 6 (2.8) 















Table 2. Non-cholesterol sterols in controls and mutation-negative FH.  
Non-cholesterol sterol ratios to 
cholesterol x103 
Controls  
(n = 97) 
Mutation-negative 
FH  
(n = 206 ) 
p 
5α-cholestanol 2.06 (1.57-2.47) 2.11 (1.66-2.89) 0.023 
β-sitosterol 1.60 (0.985-2.05) 1.84 (1.33-2.74) <0.001 
Campesterol 0.935 (0.703-1.22) 0.939 (0.699-1.33) 0.435 
Stigmasterol 0.102 (0.064-0.148) 0.171 (0.097-0.291) <0.001 
Sitostanol 0.076 (0.040-0.154) 0.046 (0.027-0.107) 0.008 
Cholesterol absorption*   4.88 (3.70-6.10) 5.24 (4.14-7.34) 0.028 
*Cholesterol absorption denotes the sum of sterol rati s to cholesterol x103 of 5α-cholestanol, β-
sitosterol, campesterol, stigmasterol and sitostanol  
Quantitative variables with not following normal distr bution were expressed as median 















Table 3. Clinical characteristics of patients carrying pathogenic mutations in ABCG5/G8 genes.  
BMI: Body mass index. TC: Total cholesterol. TG: triglyceride. ApoB: Apolipoprotein B. M: 
Men. W: Woman  
 Quantitative variables are expressed as means, except for variables not following normal 



























49 W 19.8 308 149 157 ε3/ε3 
49 W 25.5 312 180 118 ε3/ε4 
rs139264483 
c.862G>T 




58 W 25.0 316 156 136 ε2/ε3 
48 M 26.7 315 211 153 ε3/ε3 
rs552803459 
c.805G>A 
p.(Gly269Arg) 46 W 26.4 362 104 130 ε3/ε3 


















Table 4. Lipids and non-cholesterol sterols in mutation-negative FH subjects with mutation in 









( n = 199) 
p 
Age (years) 49.9 ± 3.89 46.9 ±12.5 0.111 
Sex, men, n (%) 4 (50%) 108 (52.4%) 0.893 
Body Mass Index, Kg/m2 24.5 ± 2.39 24.5 ± 2.72 0.946 
Cholesterol by HPLC MS/MS, mg/dL 296 ± 83.2 290 ± 61.1 0.820 
Triglycerides, mg/dL 157 ± 38.6 120 ± 49.8 0.039 
LDL cholesterol, mg/dL 229 (206-243) 223 (205-244) 0.760 
HDL cholesterol, mg/dL 47 (43.3-50.8) 56.0 (48.0-68.0) 0.015 
Apolipoprotein B, mg/dL 158 ± 25.9 154 ± 32.6 0.775 
5α-cholestanol-to-TC x 103 3.13 (2.05-8.59) 2.11 (1.66-2.86) 0.042 
β-sitosterol-to-TC x 103 3.03 (1.86-11.5) 1.84 (1.33-2.72) 0.045 
Campesterol-to-TC x 103 1.64 (0.907-4.94) 0.938 (0.691-1.32) 0.034 
Stigmasterol-to-TC x 103 0.447 (0.167-0.819) 0.167 (0.097-2.89) 0.047 
Sitostanol-to-TC x 103 0.084 (0.057-0.314) 0.046 (0.027-0.107) 0.088 
Cholesterol absorption† 7.97 (5.48-21.3) 5.14 (4.13-7.15) 0.030 
*Referred to patients described in detail in Table 3. 
†Cholesterol absorption denotes the sum ratios to cholesterol x103 of 5α-cholestanol, β-
sitosterol, campesterol, stigmasterol and sitostanol  
Quantitative variables are expressed as mean ± standard deviation, except for variables not 
following normal distribution that are expressed as median (interquartile range). The p value 














 Table 5. Non-cholesterol sterols in mutation-negative FH subjects with the rs2278356 variant 
and in mutation-negative FH without the rs2278356 variant. . 
 
rs2278356 
c.*380T>G   
Mutation-negative FH 







Cholesterol by HPLC MS/MS, mg/dL 292 ± 62.8 290 ± 61.1 0.838 
Triglycerides, mg/dL 118 ± 46.8 124 ± 52.8 0.317 
LDL cholesterol, mg/dL 218 (205-239) 230 (206-250) 0.021 
HDL cholesterol, mg/dL 56.0 (48.5-67.0) 55.0 (46.0-8.0) 0.459 
Apolipoprotein B, mg/dL 151 ± 33.6 157 ± 31.3 0.176 
5α-cholestanol to TC x 103 2.07 (1.69-2.82) 2.37 (1.68-3.41) 0.011 
β-sitosterol to TC x 103 1.68 (1.26-2.40) 2.28 (1.42-3.40) 0.001 
Campesterol to TC x 103 0.831 (0.642-1.31) 1.16 (0.757-1.64) 0.002 
Stigmasterol to TC x 103 0.142 (0.082-0.278) 0.179 (0.097- 0.329) 0.022 
Sitostanol to TC x 103 0.043 (0.025-0.088) 0.052 (0.027-0.116) 0.420 
Cholesterol absorption† 4.66 (4.03-6.44) 6.12 (4.34-8.32) 0.002 
†Cholesterol absorption denotes the sum ratios to cholesterol x103 of 5α-cholestanol, β-
sitosterol, campesterol, stigmasterol and sitostanol  
Quantitative variables are expressed as mean ± standard deviation, except for variables not 
following normal distribution that were expressed as median (interquartile range). ln(5α-
cholestanol to TC x 103), ln(β-sitosterol to TC x 103), ln(campesterol to TC x 103), 
ln(stigmasterol to TC x 103), ln(sitostanol to TC x 103) and ln(cholesterol absorption) were used 














Table 6. Non-cholesterol sterols in mutation-negative FH according to SNV gene score. 
 
Mutation-negative FH 
with lower gene score 
(n = 100) 
Mutation-negative FH 
with higher gene score 
(n =106) 
p 
Cholesterol by HPLC 
MS/MS, mg/dL 
282 ± 62.5 298 ± 60.3 0.074 
Triglycerides, mg/dL 121 ± 48.6 121 ± 51.3 0.967 
LDL cholesterol, mg/dL 225 (204-245) 224 (205-241) 0.586 
HDL cholesterol, mg/dL 58.5 (48.0-69.0) 55.0 (46.0-7.0) 0.420 
Apolipoprotein B, mg/dL 153 ± 34.7 155 ± 30.5 0.659 
5α-cholestanol to TC x 103 2.036 (1.65-2.82) 2.33 (1.78- 3.38) 0.034 
β-sitosterol to TC x 103 1.86 (1.31- 2.67) 1.89 (1.40-3.01) 0.149 
Campesterol to TC x 103 0.938 (0.643-1.38) 0.972 (0.761-1.56) 0.068 
Stigmasterol to TC x 103 0.129 (0.078-0.271) 0.192 (0.101-0.321) 0.029 
Sitostanol to TC x 103 0.050 (0.032- 0.097) 0.042 (0.027-1.04) 0.953 
Cholesterol absorption* 4.99 (3.97-7.06) 5.58 (4.15-8.37) 0.077 
*Cholesterol absorption denotes the sum ratios to cholesterol x103 of 5α-cholestanol, β-
sitosterol, campesterol, stigmasterol and sitostanol.  
Quantitative variables not following normal distribution were expressed as median (interquartile 
range). ln(5α-cholestanol to TC x 103), ln(β-sitosterol to TC x 103), ln(campesterol to TC x 103), 
ln(stigmasterol to TC x 103), ln(sitostanol to TC x 103) and ln(cholesterol absorption) were used 














• Phytosterols as markers of intestinal cholesterol absorption are elevated in FH- 
• The present study demonstrates an increase in ABCG5/G8 mutations in FH- 
• Subjects with mutations in ABCG5/G8 have increased plasma phytosterols 













Supplemental Table 1. Allele frequencies of genetic variants with allelic frequencies significantly different in mutation-negative FH from those identified in 


























p.(Arg50Cys) Damaging 0.047 0.067 0.243 0.076 0.0457 0.066 0.1094 
rs9789463 
c.502-395T>G 
- Benign 0.210 0.242 0.378 0.347 <0.001 0.224 0.665 
rs4549146 
c.339A>G 
p.(Val113Val) Benign 0.276 0.351 0.062 0.422 <0.001 0.4319 <0.001 
rs4557032 
c.502-192C>T 
- Benign 0.259 0.273 0.717 0.344 0.0017 - - 
rs114938914 
c.502-256G>A 
- Benign 0.040 0.062 0.225 0.077 0.0099 0.1416 0.007 
rs552803459 
c.805G>A 
p.(Gly269Arg) Damaging 0.005 0.000 0.339 0.000 0.0296 <0.001 <0.001 
rs4148187 
c.1324+164C>T 
- Benign 0.264 0.253 0.761 0.334 0.0093 - - 
rs200839584 
c.1570G>A 
p.(Val524Ile) Benign 0.005 0.000 0.339 0.000 0.0296 <0.001 <0.001 
rs150002815 
c.1320T>A p.(Asn440Lys) Benign 0.012 0.000 0.129 0.000 0.0006 <0.001 <0.001 
rs2278356 
c.*380 T>G 
- Benign 0.270 0.340 0.1183 0.320 0.0339 - - 
rs2278357 
c.*416G>A 
















- Benign 0.237 0.227 0.7791 0.297 0.0204 0.417 <0.001 
rs72647315 
c.-15A>C 
- Benign 0.050 0.050 0.9390 0.000 0.0296 0.000 <0.001 
rs11887534 
c.55G>A 
p.(Asp19Asn) Benign 0.042 0.096 0.0082 0.080 0.0107 0.077 0.007 
rs4148209 
c.64-21C>A 
- Benign 0.291 0.273 0.6476 0.371 0.0038 0.388 <0.001 
rs4148210 
c.64-7C>T 
- Benign 0.275 0.278 0.9243 0.372 <0.001 0.386 <0.001 
rs4148211 
c.161A>G 
p.(Tyr54Cys) Benign 0.279 0.273 0.8741 0.371 <0.001 0.387 <0.001 
rs4148213 
c.165+105G>C 
- Benign 0.296 0.278 0.6576 0.372 0.0058 - - 
rs4148214 
c.561+43T>C 
- Benign 0.322 0.412 0.0280 0.461 <0.001 0.561 <0.001 
rs114197606 
c.964+178G>A 






0.002 0.000 0.4494 0.000 0.0025 0.000 <0.001 
rs4148217 
c.1199C>A 
p.(Thr400Lys) Benign 0.033 0.000 0.0105 0.201 <0.001 0.2146 <0.001 
rs4245794 
c.1212-77T>C 
- Benign 0.068 0.093 0.2811 0.107 0.0209 - - 
rs34198326 
c.1411+104A>G 
- Benign 0.052 0.124 0.0015 0.090 0.0128 - - 
rs371711306 
c.1845G>C 
p.(Met615Ile) Benign 0.050 0.000 0.3403 0.000 0.030 0.000 <0.001 
rs55741639 
c.965-58A>G 
- Benign 0.023 0.000 0.0314 0.016 0.2072 - - 
rs4953027 
c.1412-152A>G 















- Benign 0.132 0.240 0.0009 0.153 0.3054 - - 
rs28517482 
c.1412-8C>T 
- Benign 0.343 0.196 0.0002 0.397 0.0548 0.599 <0.001 
The p value was calculated by Chi-square test, by comparing mutant versus wild-type allelic frequencies between mutation-negative FH and controls (p1), 
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Supplemental Table 3. Cholesterol synthesis markers in mutation-negative FH subjects with 
mutation in ABCG5/G8 genes and in mutation-negative FH without mutations in ABCG5/G8 
genes.  
 
 Mutation-negative FH 
with ABCG5/G8 
mutation* 




( n = 199) 
p 
Lanosterol-to-TC x 103 0.11 (0.05-0.31) 0.11 (0.07-0.16) 0.961 
Desmosterol -to-TC x 103 2.18 (0.89-6.12) 2.24 (1.73-2.91) 0.940 
*Referred to patients described in detail in Table 3. 
Lanosterol and demosterol are expressed as ratios to cholesterol x 103 
Variables are expressed as median (interquartile range). The p value was calculated by Mann-
Whitney U.  
  
